
Personal experience on Rare Disease Day from Katie Allen, from CMTC-OVM Katie is one of our Patient Advocates from Canada and shares a bit of her experience. We not only …
Personal experience on Rare Disease Day from Katie Allen, from CMTC-OVM Katie is one of our Patient Advocates from Canada and shares a bit of her experience. We not only …
The situation in and around Ukraine continues to evolve at a fast pace, and the needs of people with a rare disease affected by the war are changing. Even so, …
The ECRD is recognised globally as the largest, patient-led rare disease policy event in which collaborative dialogue, learning and conversation takes place, forming the groundwork to shape goal-driven rare disease …
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals …
Many chronic diseases are present at birth and, as time passes by, children with the chronic disease need medical treatments that could be physically painful. This could cause additional psychological …
Seinäjoki University of Applied Science project named TATTI – Using Technology to Make Work Productive and Safe aims to prevent musculoskeletal disorders. The primary goal of the TATTI-project is to …
This is the fifth article of the Dutch, global and non-profit patient organisation for patients with CMTC and other vascular (bloodvessel) malformations, families and healthcare providers. In this edition, we …
As a second emerging crisis of the pandemic comes to light, 10% of all ‘mildly’ affected patients with COVID-19 have not recovered within 14 months of the initial infection (referred …
The global CMTC-OVM organisation has its own online Community. The main reason is the misuse of personal data by eg Facebook and Google. This application is running on a secure …
This magazine was created on the initiative of the European Patient Advocacy Group (ePAG) members of the Vascular Anomalies Working Group(VASCA WG) in VASCERN and was kindly supported financially by …